Unique solutions in immunology and beyond
Therapies for autoreactive immune disorders have greatly advanced in the past decades but often have significant side effects. Marinomed Biotech AG strives to improve therapies by increasing the solubility and bioavailability of existing drugs. A proprietary pipeline and Solv4U, a B2B offering for API solubilization, enable the development of clinically meaningful new or improved therapies.
Austrian biopharmaceutical company Marinomed has the vision to transform the lives of patients with limited or no treatment options in two key therapeutic areas: virology and immunology. In virology, the company has an outstanding global track record in the OTC segment with clinically proven, effective virus-blocking Carragelose-based products on the market. Rx treatments for severe viral infections, including viral pneumonia, are in development. In immunology, Marinomed focuses on finding innovative treatments for autoreactive immune disorders.
Clinically validated solutions
Many approaches modulating autoreactive immune responses are broadly active, systemic therapies. They can cause severe side effects, including an increased susceptibility to infections and cancer. Marinomed wants to change this: their proprietary Marinosolv technology enables solubilization of even highly hydrophobic APIs. This allows a significant decrease of dose while improving efficacy through increased local bioavailability in target tissues and reducing the environmental footprint at the same time.
The power and safety of Marinosolv are clinically validated: Budesolv, a nasal spray containing dissolved budesonide, has successfully completed a Phase III pivotal study, where less than 16% of the regular dose relieved symptoms of allergic rhinitis with onset of action within two hours after the first application. Budesolv is licensed for development and future commercialization in Greater China, and available for partnering in other regions.
Marinomed has identified a first target indication: herpetic stromal keratitis (HSK), a viral infectious eye disease that can lead to vision loss due to an overshooting T cell response. While tacrolimus is a potent inhibitor of T cell activation, its low water solubility has hampered its use in ophthalmology. Tacrosolv is a Marinosolv-based tacrolimus eye drop formulation for this orphan indication. A Phase II clinical study has proven anti-inflammatory efficacy. Further clinical development specifically in patients suffering from HSK is in preparation.
Solutions for you
Improving solubility is a critical step in pharmaceutical development beyond immunological indications. Therefore, Marinomed offers Solv4U technology partnerships based on Marinosolv in all stages of drug discovery. Marinosolv formulations are eligible for patent protection even if the APIs themselves are not. With its innovative approach, Marinomed strives to create value for patients, clients, and other stakeholders.
Contact us:
Marinomed Biotech AG
bd@marinomed.com
https://www.marinomed.com
https://www.solv4u.com
Biocytogen Co Ltd
Draupnir Bio ApS